Document is current
Any future updates will be listed below
-
Authors
Plym, Anna https://orcid.org/0000-0001-6351-4744
Wang, Anqi
Stopsack, Konrad H. https://orcid.org/0000-0002-0722-1311
Zhang, Yiwen
Baras, Aris
,
Drake, Isabel https://orcid.org/0000-0002-6500-6310
Clements, Mark
Penney, Kathryn L.
Giovannucci, Edward https://orcid.org/0000-0002-6123-0219
Kibel, Adam S.
Mucci, Lorelei A.
Wiklund, Fredrik https://orcid.org/0000-0002-4623-0544
- License Information
-
More Information
Article History
Received: 27 October 2025
Accepted: 10 April 2026
First Online: 24 April 2026
Competing interests
: K.L.P. reports research grants/funding from Janssen. L.A.M. reports equity interest in Convergent Therapeutics, unrelated to this work. A.S.K. reports honoraria from Profound, Pfizer, Janssen, and Merck; has served as a consultant for Bristol Myers Squibb and Candel. A.B. is employed by Regeneron Genetics Center. The remaining authors declare no competing interests.
